Avancerad sökning

Visar resultat 1 - 5 av 14 avhandlingar som matchar ovanstående sökkriterier.

  1. 1. Identifying Essential Deubiquitinase Interactions and Targeting Protein Ubiquitination in Cancer

    Författare :Johannes Gubat; Padraig D´arcy; Stig Linder; Maria Turkina; Per Lindahl; Linköpings universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Cancer; Deubiquitinase; b-AP15; Ubiquitin-proteasome system;

    Sammanfattning : Cancer is the second leading cause of death globally and is one of the most pressing health issues today. While significant advances have been made in cancer treatment, drug resistance and toxicity remain formidable obstacles to successful therapy. Thus, there is a need to find novel targets that pave the way for new cancer therapeutics. LÄS MER

  3. 2. Potential New Drugs in Lymphoma

    Författare :Maryam Delforoush; Gunilla Enblad; Mattias Berglund; Christina Drott; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; lymphoma; diffuse large B-cell lymphoma; DLBCL; picropodophyllin; PPP; J1; melflufen; prodrug; cancer therapeutics; alkylating agents; b-AP15; proteasome inhibitors; DUB inhibition; UCHL5; USP14;

    Sammanfattning : Lymphomas are malignant tumours arising from cells in the lymphatic system. They are classified as B-cell lymphomas, T-cell lymphomas and Hodgkin lymphoma (HL). Of the B-cell lymphomas, one of the most common is diffuse large B-cell lymphoma (DLBCL). LÄS MER

  4. 3. Studies of b-AP15 : a novel inhibitor of proteasome deubiquitinase activity

    Författare :Chao Sun; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : Bortezomib was the first FDA approved proteasome inhibitor that was initially very successful in treatment of multiple myeloma patients but acquired resistance and adverse side-effect highly decreased patients’ quality of life. Development of 2nd generation proteasome inhibitors that could overcome these shortcomings is thus of prime medical importance. LÄS MER

  5. 4. Identification and characterization of a proteasome deubiquitinase inhibitor

    Författare :Slavica Brnjic; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : The 26S proteasome has emerged as an attractive therapeutic target in the treatment of cancers. Proteasome inhibitors have been shown to selectively kill cancer cells. The FDA approval of bortezomib for the treatment of multiple myeloma and mantle cell lymphoma has clinically validated the 26S proteasome as a therapeutic target in oncology. LÄS MER

  7. 5. Mechanistic studies of a novel inhibitor of the ubiquitin-proteasome system

    Författare :Ellin-Kristina Hillert; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : The ubiquitin-proteasome system (UPS) not only maintains cellular proteostasis, but plays an essential role in multiple vital cellular processes, including survival and growth. Proteasomal inhibitors, such as bortezomib, have been shown to have effective anti-cancer properties, verifying the UPS as a viable drug target in cancer treatment. LÄS MER